Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Blueprint Medicines
Sort By
Newest First
1 / 1
1 / 1
FDA Approval
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Blueprint Medicines
PR-M11-20-027
Dec 02, 2020
Collaboration
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Blueprint Medicines
PR-M07-20-NI-023
Jul 15, 2020
Market Expansion
BluePrint Medicines Targets Asian Market
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M06-18-NI-002
Jun 05, 2018
